Ropes & Gray advised Generate Biomedicines in a multi-target strategic collaboration and licensing agreement with Zealand Pharma to develop protein therapeutics for obesity and metabolic diseases using an AI platform for up to $1.2 billion. The deal was announced on October 13.
Under the agreement, Generate will use its generative AI platform to lead research through lead-candidate selection. Zealand Pharma will assume responsibility for subsequent clinical development, regulatory submissions, and worldwide commercialization.
For the first two programs, Generate will receive $30 million and up to $35 million in early preclinical milestones, and is eligible for total milestones of nearly $1.2 billion, including potential development, regulatory and commercial milestones, plus tiered royalties on future worldwide net sales of any commercialized products resulting from the collaboration.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and associate James Gould.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.